Topics:

ASH 2013

ASH 2013

Cancer Network presents exclusive coverage from the American Society of Hematology (ASH) annual meeting. We'll bring you onsite reports as we cover the latest research, trials, scientific advances, and controversies that are changing the way hematologic malignancies are managed and treated.

Check back here daily during the meeting and watch your inbox for our exciting reports from the ASH 2013 meeting.

ASH 2013

A phase III trial of idelalisib plus rituximab in patients with previously treated chronic lymphocytic leukemia found that the combo improved progression-free and overall survival, according to results presented at the 2013 ASH meeting.

In a study presented at the 2013 ASH meeting, researchers showed evidence that p53 mutations are already present in patients who develop treatment-related MDS and AML, results which could help identify high-risk patients prior to cytotoxic therapy.

Treatment with gemtuzumab ozogamicin improved the event-free survival in children and adolescents with acute myeloid leukemia by reducing the risk of relapse among those able to achieve remission, according to trial results presented at the 2013 ASH meeting.

In a 12-patient multiple myeloma pilot study, researchers demonstrated that anti-CD3 and anti-CD20 bispecific antibody (CD20Bi) activated both cellular and humoral anti-myeloma immunity that was detectable after patients received an autologous stem cell transplant.

In a late-breaking abstract presentation, Thorsten Klampfl, PhD, of the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna, presented data from a whole exome study of primary myelofibrosis patients, identifying a new specific molecular mutation

In this video, Dr. Mikhael discusses the current treatment paradigm for multiple myeloma and highlights some of the new agents in development.

Patients with the rare and potentially deadly multicentric Castleman disease were able to achieve durable tumor and symptomatic response when assigned to treatment with the monoclonal antibody siltuximab, according to data presented at the 2013 ASH meeting.

Pages

Subscribe to ASH 2013 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.